Share on StockTwits

Equities researchers at Robert W. Baird initiated coverage on shares of Enanta Pharmaceuticals (NASDAQ:ENTA) in a research report issued on Monday, reports. The firm set an “outperform” rating on the stock.

ENTA has been the subject of a number of other recent research reports. Analysts at Zacks downgraded shares of Enanta Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note to investors on Wednesday, January 1st. They now have a $33.30 price target on the stock. One research analyst has rated the stock with a hold rating and five have given a buy rating to the company. Enanta Pharmaceuticals has a consensus rating of “Buy” and a consensus price target of $31.15.

Shares of Enanta Pharmaceuticals (NASDAQ:ENTA) traded down 0.33% on Monday, hitting $29.93. 209,746 shares of the company’s stock traded hands. Enanta Pharmaceuticals has a 1-year low of $14.31 and a 1-year high of $38.48. The stock’s 50-day moving average is $31.22 and its 200-day moving average is $22.94. The company’s market cap is $537.6 million.

Enanta Pharmaceuticals (NASDAQ:ENTA) last released its earnings data on Monday, November 25th. The company reported ($0.25) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.29) by $0.04. The company had revenue of $1.30 million for the quarter, compared to the consensus estimate of $1.00 million. On average, analysts predict that Enanta Pharmaceuticals will post $1.20 earnings per share for the current fiscal year.

Enanta Pharmaceuticals, Inc is a research and development-focused biotechnology company. The Company uses its chemistry-driven approach and drug discovery capabilities to create small molecule drugs in the infectious disease field.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.